Prab: CSV import

2025-02-15T11:39:56Z

CSV import

← Older revision		Revision as of 11:39, 15 February 2025
Line 1:		Line 1:
	~~'''~~Givinostat''' is a potent [[histone deacetylase inhibitor]] (HDAC inhibitor) that is under investigation for its potential therapeutic applications in various medical conditions, including [[cancer]], [[juvenile idiopathic arthritis]], and [[Duchenne muscular dystrophy]]. As an HDAC inhibitor, Givinostat works by interfering with the function of histone deacetylases, enzymes involved in the removal of acetyl groups from the lysine residues on histone proteins. This action leads to an open chromatin structure and affects gene expression, which can inhibit the proliferation of cancer cells and modulate inflammatory responses.		== Givinostat ==

	~~==Mechanism of Action==~~		[[File:Givinostat_structure.svg\|thumb\|right\|Chemical structure of Givinostat]]
	Givinostat inhibits the activity of histone deacetylases, which are key enzymes in the regulation of gene expression. By inhibiting these enzymes, Givinostat increases the acetylation of histone proteins, leading to an open chromatin structure. ~~This change in chromatin~~ structure ~~enhances the transcription~~ of genes involved in cell cycle arrest, apoptosis, and the suppression of inflammatory gene expression. The exact mechanism of action may vary depending on the type of cells and the pathological condition being treated.

	~~==Clinical Trials and Research==~~		'''Givinostat''' is a [[histone deacetylase inhibitor]] (HDAC inhibitor) that has been studied for its potential therapeutic effects in various [[diseases]], including [[cancer]] and [[inflammatory disorders]]. It is a small molecule that interferes with the function of histone deacetylases, enzymes that play a critical role in the regulation of [[gene expression]] by modifying the acetylation status of histones and other proteins.
	Givinostat has been ~~the subject of numerous clinical trials, exploring~~ its ~~efficacy and safety~~ in ~~treating~~ various diseases~~. For instance, in oncology, it has been evaluated for its potential to treat multiple myeloma, lymphomas~~, and ~~solid tumors~~. In the ~~context~~ of ~~inflammatory diseases~~, ~~research has focused on its ability to modulate immune responses in conditions like juvenile idiopathic arthritis. Additionally, its~~ role in ~~Duchenne muscular dystrophy is being investigated, with studies suggesting that Givinostat may improve muscle function~~ and ~~reduce inflammation~~.

	==~~=Cancer=~~==		== Mechanism of Action ==
	In cancer treatment, Givinostat has shown promise in preclinical and early clinical trials by inducing apoptosis and cell cycle arrest in cancer cells. Its ability to modulate the expression of genes involved in cancer cell survival and proliferation makes it a potential candidate for combination therapy with other anticancer agents.

	~~===Juvenile Idiopathic Arthritis===~~		Givinostat exerts its effects by inhibiting the activity of histone deacetylases, leading to an accumulation of acetylated histones and other proteins. This results in changes in chromatin structure and the activation or repression of specific genes. The inhibition of HDACs by Givinostat can induce [[cell cycle arrest]], promote [[apoptosis]], and modulate [[immune responses]].
	~~For juvenile idiopathic arthritis,~~ Givinostat ~~has been explored for~~ its ~~anti-inflammatory properties. By~~ inhibiting the ~~production~~ of ~~pro-inflammatory cytokines~~ and ~~modulating immune~~ cell ~~function~~, ~~Givinostat may offer a novel approach to managing this condition~~.

	===~~Duchenne Muscular Dystrophy~~===		== Clinical Applications ==
	In Duchenne muscular dystrophy, Givinostat's potential to improve muscle function and reduce muscle fibrosis has been a focus of research. Early studies suggest that Givinostat may enhance muscle regeneration and decrease inflammatory responses in muscle tissue.

	~~==Safety and Side Effects==~~		Givinostat has been investigated in clinical trials for its potential use in treating various conditions:
	~~As with any investigational drug, the safety profile of~~ Givinostat ~~is a critical aspect of its development. Common side effects observed~~ in clinical trials include fatigue, nausea, and thrombocytopenia. However, the severity and incidence of side effects can vary depending on the dosage and the patient population. Ongoing and future clinical trials will further elucidate the safety and tolerability of Givinostat.

	~~==Regulatory Status==~~		* '''Cancer''': Givinostat has shown promise in the treatment of certain types of cancer, including [[leukemia]] and [[lymphoma]]. By altering gene expression, it can inhibit the proliferation of cancer cells and induce their death.
	~~As of the last update,~~ Givinostat has ~~not received approval from regulatory agencies such as~~ the [[~~U.S. Food and Drug Administration~~]] ~~(FDA) or the~~ [[~~European Medicines Agency~~]] ~~(EMA) for any indication~~. ~~Its development and evaluation in clinical trials continue~~, ~~with~~ the ~~aim~~ of ~~establishing its efficacy~~ and ~~safety for potential therapeutic use~~.

	~~[[Category:Experimental drugs]]~~		* '''Inflammatory Disorders''': The drug has also been studied for its effects on inflammatory diseases such as [[rheumatoid arthritis]] and [[systemic lupus erythematosus]]. Its ability to modulate immune responses makes it a candidate for treating these conditions.
	~~[[Category:Epigenetics]]~~
	~~[[Category~~:~~Oncology]]~~
	[[~~Category:Rheumatology~~]]
	[[~~Category:Muscular dystrophy~~]]

	{{Pharmacology~~-stub}}~~		== Pharmacokinetics ==
	~~{{Medicine~~-~~stub}}~~
			The pharmacokinetic profile of Givinostat involves its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug's half-life and bioavailability are important factors in determining its dosing regimen.

			== Side Effects ==

			Like many HDAC inhibitors, Givinostat can cause a range of side effects. Common adverse effects include [[gastrointestinal disturbances]], [[fatigue]], and [[hematological abnormalities]]. Monitoring and management of these side effects are crucial during treatment.

			== Research and Development ==

			Ongoing research is focused on understanding the full potential of Givinostat in various therapeutic areas. Studies are exploring its use in combination with other drugs to enhance efficacy and reduce resistance.

			== Related Pages ==

			* [[Histone deacetylase inhibitor]]
			* [[Cancer therapy]]
			* [[Inflammatory disease]]

			[[Category:Pharmacology]]
			[[Category:Antineoplastic drugs]]
			[[Category:Anti-inflammatory agents]]

Prab: CSV import

2024-03-22T12:33:06Z

CSV import

New page

'''Givinostat''' is a potent [[histone deacetylase inhibitor]] (HDAC inhibitor) that is under investigation for its potential therapeutic applications in various medical conditions, including [[cancer]], [[juvenile idiopathic arthritis]], and [[Duchenne muscular dystrophy]]. As an HDAC inhibitor, Givinostat works by interfering with the function of histone deacetylases, enzymes involved in the removal of acetyl groups from the lysine residues on histone proteins. This action leads to an open chromatin structure and affects gene expression, which can inhibit the proliferation of cancer cells and modulate inflammatory responses.

==Mechanism of Action==
Givinostat inhibits the activity of histone deacetylases, which are key enzymes in the regulation of gene expression. By inhibiting these enzymes, Givinostat increases the acetylation of histone proteins, leading to an open chromatin structure. This change in chromatin structure enhances the transcription of genes involved in cell cycle arrest, apoptosis, and the suppression of inflammatory gene expression. The exact mechanism of action may vary depending on the type of cells and the pathological condition being treated.

==Clinical Trials and Research==
Givinostat has been the subject of numerous clinical trials, exploring its efficacy and safety in treating various diseases. For instance, in oncology, it has been evaluated for its potential to treat multiple myeloma, lymphomas, and solid tumors. In the context of inflammatory diseases, research has focused on its ability to modulate immune responses in conditions like juvenile idiopathic arthritis. Additionally, its role in Duchenne muscular dystrophy is being investigated, with studies suggesting that Givinostat may improve muscle function and reduce inflammation.

===Cancer===
In cancer treatment, Givinostat has shown promise in preclinical and early clinical trials by inducing apoptosis and cell cycle arrest in cancer cells. Its ability to modulate the expression of genes involved in cancer cell survival and proliferation makes it a potential candidate for combination therapy with other anticancer agents.

===Juvenile Idiopathic Arthritis===
For juvenile idiopathic arthritis, Givinostat has been explored for its anti-inflammatory properties. By inhibiting the production of pro-inflammatory cytokines and modulating immune cell function, Givinostat may offer a novel approach to managing this condition.

===Duchenne Muscular Dystrophy===
In Duchenne muscular dystrophy, Givinostat's potential to improve muscle function and reduce muscle fibrosis has been a focus of research. Early studies suggest that Givinostat may enhance muscle regeneration and decrease inflammatory responses in muscle tissue.

==Safety and Side Effects==
As with any investigational drug, the safety profile of Givinostat is a critical aspect of its development. Common side effects observed in clinical trials include fatigue, nausea, and thrombocytopenia. However, the severity and incidence of side effects can vary depending on the dosage and the patient population. Ongoing and future clinical trials will further elucidate the safety and tolerability of Givinostat.

==Regulatory Status==
As of the last update, Givinostat has not received approval from regulatory agencies such as the [[U.S. Food and Drug Administration]] (FDA) or the [[European Medicines Agency]] (EMA) for any indication. Its development and evaluation in clinical trials continue, with the aim of establishing its efficacy and safety for potential therapeutic use.

[[Category:Experimental drugs]]
[[Category:Epigenetics]]
[[Category:Oncology]]
[[Category:Rheumatology]]
[[Category:Muscular dystrophy]]

{{Pharmacology-stub}}
{{Medicine-stub}}

Givinostat - Revision history

Prab: CSV import

Prab: CSV import